FGFR2 and intrahepatic cholangiocarcinoma: Single-arm study have already demonstrated the clinical benefits of FGFR inhibitor (Futibatinib) in previously treated patients with FGFR2 fusion or rearrangement-positive intrahepatic cholangiocarcinoma [59].